Literature DB >> 10543611

High-capacity adenoviral vectors for gene transfer and somatic gene therapy.

S Kochanek1.   

Abstract

The availability of efficient and nontoxic gene delivery technologies is fundamental to the translation of therapeutic concepts into clinical practice by gene transfer. High-capacity adenoviral (HC-Ad) vectors are characterized by the ability to transduce cells in vitro and in vivo with more than 30 kb of nonviral DNA. This quality allows simultaneous gene transfer of several expression cassettes, large promoters, and some genes in their natural genomic context. Because all viral coding sequences are removed from these vectors, safety is considerably improved compared with previous-generation adenoviral vectors.

Entities:  

Mesh：

Year:  1999        PMID： 10543611     DOI： 10.1089/10430349950016807

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


  36 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

3.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector.

Authors:  Shuji Kubo; Kohnosuke Mitani
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 5.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

6.  Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors.

Authors:  Florian Kreppel; Stefan Kochanek
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Mol Brain Res       Date:  2005-04-18

8.  Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye.

Authors:  Irina Semkova; Florian Kreppel; Gerhard Welsandt; Thomas Luther; Jolanta Kozlowski; Hanna Janicki; Stefan Kochanek; Ulrich Schraermeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-18       Impact factor: 11.205

Review 9.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

10.  Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo.

Authors:  Melanie Fiedler; Florian Rödicker; Valentina Salucci; Mengji Lu; Luigi Aurisicchio; Uta Dahmen; Li Jun; Olaf Dirsch; Brigitte M Pützer; Fabio Palombo; Michael Roggendorf
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.